<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136458</url>
  </required_header>
  <id_info>
    <org_study_id>ValledelLili</org_study_id>
    <nct_id>NCT03136458</nct_id>
  </id_info>
  <brief_title>Efficacy of Remote Ischemic Preconditioning as Non Pharmacologic Strategy to Prevent Contrast Induced Nephropathy (PAIR)</brief_title>
  <acronym>PAIR</acronym>
  <official_title>Efficacy of Remote Ischemic Preconditioning as Non Pharmacologic Strategy to Prevent Contrast Induced Nephropathy (PAIR Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camilo Andrés Páez Angarita</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinica Valle del Lili</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates remote ischemic preconditioning as an strategy to avoid contrast induced
      nephropathy. All of the patients will receive endovenous normal saline to prevent
      nephropathy, half of the patients will receive remote ischemic preconditioning while the
      other half will not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates remote ischemic preconditioning as an strategy to avoid contrast induced
      nephropathy, this preconditioning is administered through repeated insufflation of an
      arterial pressure cuff in one of the patient arms, which in theory liberates vasoactive
      mediators that prevents the ischemic damage to the kidneys secondary to contrast media. All
      of the patients will receive endovenous normal saline to prevent nephropathy, which is a
      common strategy in our institution. Half of the patients will receive remote ischemic
      preconditioning while the other half will only receive a dummy preconditioning intended to
      keep the double blind strategy of the trial.

      The main endpoint will be to ascertain the incidence of contrast induced nephropathy in both
      arms of the study, as a way to evaluate the efficacy of this strategy.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    No resources
  </why_stopped>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast induced nephropathy incidence</measure>
    <time_frame>48 to 72 hours</time_frame>
    <description>Increase in serum creatinine by 0,3 mg/dL compared to initial values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects to preconditioning.</measure>
    <time_frame>0 to 72 hours.</time_frame>
    <description>Any of pain in upper extremities, petechiae, bleeding from venopuncture sites, erythema.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Contrast-induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>Real ischemic preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dummy ischemic preconditioning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ischemic preconditioning</intervention_name>
    <description>Repeated remote ischemic preconditioning by arterial cuff insufflation.</description>
    <arm_group_label>Real ischemic preconditioning</arm_group_label>
    <other_name>remote ischemic preconditioning</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endovenous normal saline</intervention_name>
    <description>endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.</description>
    <arm_group_label>Real ischemic preconditioning</arm_group_label>
    <arm_group_label>Dummy ischemic preconditioning</arm_group_label>
    <other_name>normal saline 0,9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized in general wards, emergency room or ambulatory consult.

          -  18 years or older.

          -  Requires computerized tomography with endovenous contrast.

          -  Glomerular filtration rate between 30 - 60 mL/minute/1,73 m2.

          -  Patient accepts and signs informed consent.

        Exclusion Criteria:

          -  Allergic to contrast media.

          -  Unable to accept or sign informed consent.

          -  Did not received endovenous saline before and/or after the contrast procedure.

          -  Peripheral arterial disease.

          -  Bilateral upper extremities lymph node dissection or any situation impending arterial
             pressure taking.

          -  Morbid obesity (body mass index 40 or more).

          -  Arterial systolic pressure greater than 175 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grupo Nefrología Fundación Valle del Lili</name>
      <address>
        <city>Cali</city>
        <state>Valle del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol. 2008 Jan;3(1):263-72. doi: 10.2215/CJN.03690907. Review.</citation>
    <PMID>18178787</PMID>
  </reference>
  <reference>
    <citation>Hölscher B, Heitmeyer C, Fobker M, Breithardt G, Schaefer RM, Reinecke H. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol. 2008 Nov;24(11):845-50.</citation>
    <PMID>18987758</PMID>
  </reference>
  <reference>
    <citation>Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005 May 24;172(11):1461-71. Review. Erratum in: CMAJ. 2005 Nov 8;173(10):1210.</citation>
    <PMID>15911862</PMID>
  </reference>
  <reference>
    <citation>Bonventre JV. Limb ischemia protects against contrast-induced nephropathy. Circulation. 2012 Jul 24;126(4):384-7. doi: 10.1161/CIRCULATIONAHA.112.119701. Epub 2012 Jun 26.</citation>
    <PMID>22735307</PMID>
  </reference>
  <reference>
    <citation>Gassanov N, Nia AM, Caglayan E, Er F. Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? J Am Soc Nephrol. 2014 Feb;25(2):216-24. doi: 10.1681/ASN.2013070708. Epub 2013 Dec 5. Review.</citation>
    <PMID>24309187</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>July 22, 2017</last_update_submitted>
  <last_update_submitted_qc>July 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinica Valle del Lili</investigator_affiliation>
    <investigator_full_name>Camilo Andrés Páez Angarita</investigator_full_name>
    <investigator_title>Internal Medicine Resident</investigator_title>
  </responsible_party>
  <keyword>contrast media</keyword>
  <keyword>nephropathy</keyword>
  <keyword>ischemic preconditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

